ENTEROME, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics, has entered into a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) in New York City to evaluate the potential of gut microbiome-derived antigens for development as cancer immunotherapies.
Enterome is pioneering an innovative approach to cancer immunotherapy based on the concept of “molecular mimicry”, whereby microbiome-derived bacterial antigens that show molecular similarity with Tumor-associated Antigens (TAAs) and Tumor-specific Neoantigens (TSNAs) are used to trigger tumor-specific cytotoxic T cell immune responses. The Company refers to these bacterial antigens as “onco-mimics.”